Dupixent® (dupilumab) sBLA Accepted for FDA Priority Re

Priority Review granted based on positive results from two Phase 3 trials; if approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for

Related Keywords

Japan , Paris , France General , France , China , Georged Yancopoulos , Vesna Tosic , Hannah Kwagh , Regeneron Velocimmune , Dupilumab Development Program , Linkedin , Euronext , Exchange Commission , Nasdaq , Clinical Research Program , Drug Administration , Regeneron Pharmaceuticals Inc , Regeneron Genetics Center , Priority Review , Biologics License Application , Chief Scientific Officer , Nasal Polyposis , Prescribing Information , Forward Looking Statements , Regeneron Pharmaceuticals , Product Candidates , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Nation World , Region ,